Trade Report: The BMO Capital Markets Reiterates “Outperform” Rating for Jazz Pharmaceuticals PLC (JAZZ)

The BMO Capital Markets Reiterates “Outperform” Rating for Jazz Pharmaceuticals PLC (JAZZ)

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)‘s stock had its “outperform” rating reaffirmed by equities researchers at BMO Capital Markets in a research report issued on Friday. They presently have a $195.00 price objective on the specialty pharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 58.78% from the company’s current price.

Other research analysts have also issued research reports about the company. Wells Fargo & Co. reiterated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research report on Saturday, June 18th. Deutsche Bank AG reiterated a “buy” rating and issued a $158.00 target price (up previously from $155.00) on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 11th. Barclays PLC reiterated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, August 10th. Mizuho decreased their target price on Jazz Pharmaceuticals PLC from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, August 10th. Finally, Leerink Swann reiterated a “buy” rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and fourteen have assigned a buy rating to the company’s stock. Jazz Pharmaceuticals PLC has a consensus rating of “Buy” and an average price target of $185.00.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 0.08% on Friday, reaching $122.81. The company had a trading volume of 371,790 shares. Jazz Pharmaceuticals PLC has a 12 month low of $108.50 and a 12 month high of $160.00. The company has a market capitalization of $7.43 billion, a price-to-earnings ratio of 21.59 and a beta of 0.96. The stock has a 50 day moving average price of $125.64 and a 200-day moving average price of $139.49.

10/07/bmo-capital-markets-reiterates-outperform-rating-for-jazz-pharmaceuticals-plc-jazz.html

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $2.63 EPS for the quarter, missing the consensus estimate of $2.80 by $0.17. The firm earned $381 million during the quarter, compared to analyst estimates of $376.40 million. Jazz Pharmaceuticals PLC had a return on equity of 28.39% and a net margin of 25.46%. Jazz Pharmaceuticals PLC’s revenue was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.41 EPS. Analysts forecast that Jazz Pharmaceuticals PLC will post $9.97 EPS for the current fiscal year.

In other news, CMO Karen L. Smith acquired 580 shares of the company’s stock in a transaction dated Wednesday, July 13th. The shares were bought at an average price of $143.63 per share, with a total value of $83,305.40. Following the purchase, the chief marketing officer now owns 13,574 shares of the company’s stock, valued at $1,949,633.62. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $150.00, for a total value of $150,000.00. The disclosure for this sale can be found here. Company insiders own 3.90% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. BlackRock Fund Advisors increased its stake in Jazz Pharmaceuticals PLC by 3.2% in the first quarter. BlackRock Fund Advisors now owns 1,527,156 shares of the specialty pharmaceutical company’s stock worth $199,370,000 after buying an additional 47,265 shares in the last quarter. State Street Corp boosted its position in shares of Jazz Pharmaceuticals PLC by 7.7% in the first quarter. State Street Corp now owns 1,333,938 shares of the specialty pharmaceutical company’s stock worth $174,128,000 after buying an additional 95,849 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Jazz Pharmaceuticals PLC by 4.2% in the second quarter. Bank of New York Mellon Corp now owns 1,233,053 shares of the specialty pharmaceutical company’s stock worth $174,242,000 after buying an additional 49,967 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Jazz Pharmaceuticals PLC by 20.0% in the first quarter. JPMorgan Chase & Co. now owns 1,074,731 shares of the specialty pharmaceutical company’s stock worth $140,307,000 after buying an additional 179,454 shares during the last quarter. Finally, Prudential Financial Inc. boosted its position in shares of Jazz Pharmaceuticals PLC by 2.0% in the second quarter. Prudential Financial Inc. now owns 620,397 shares of the specialty pharmaceutical company’s stock worth $87,668,000 after buying an additional 12,320 shares during the last quarter. 88.25% of the stock is currently owned by institutional investors.

About Jazz Pharmaceuticals PLC

Related posts

Leave a Comment